In 1991, up to 40% of failures in the clinical phase of new drug development were associated with drug DMPK properties; in 2000, the likelihood of late failure was dramatically reduced to less than 10% as major pharmaceutical companies shifted to early DMPK studies.
(1) Early pharmacokinetic testing allows for a low-cost, short-term risk-benefit assessment of new drug development projects.
(2) Guiding the processes from optimization of lead compounds to determination of preclinical drug candidates.